12.08.08

VitiGam™ Inhibits Melanoma Growth in a Dose Dependent Manner. Inhibition of Tumor Growth is Statistically Significant

04.06.08

GammaCan Executes Supply Agreement with Bio Products Laboratory to Manufacture VitiGam™ for the Treatment of Melanoma for Clinical Testing and Commercial Sale

01.04.08

GammaCan Announces Positive Testing Results in the Development of VitiGam™ for the Treatment of Melanoma

05.11.07

GammaCan Presents at the Rodman & Renshaw 9th Annual Healthcare Conference 2007

01.10.2007

GammaCan Enters Into Vitiligo Plasma Supply Agreement With DCI Biologicals

07.08.2007

GammaCan Receives FDA Orphan Drug Designation for Lead Product VitiGam(TM) for Stage IIB to Stage IV Melanoma

28.06.2007

GammaCan Discovers Anti-Angiogenic Properties in Plasma-Derived IgG

27.06.2007

GammaCan Retains Investor Relations Firm ROI Group

06.06.2007

GammaCan to Present its Anti-Melanoma Technology at the 2007 ILSI BioMed Conference

14.05.2007

GammaCan to Present and Webcast at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference

28.02.2007

GammaCan Signs USD 6.5 Million Private Placement with Institutional Investors

01.02.2007

GammaCan International to Present IgG-Based Melanoma Program at the 5th Annual BioPartnering North America

04.01.2007

GammaCan Files Additional Patent Applications Covering the Treatment of Malignant Melanoma and Colorectal Cancer with the United States Patent and Trademark Office

13.12.2006

GammaCan International, Inc. to Highlight its Melanoma Program on MN1.com

12.12.2006

GammaCan International to Present at the Israeli Equities Conference in New York City

16.11.2006

GammaCan International Reorganizes Board of Directors

06.11.2006

GammaCan International to Present at the PIPEs Conference 2006 in New York City

2.11.2006

GammaCan International to Present at the 8th Annual Rodman & Renshaw Global Healthcare Conference in New York City

31.10.2006

GammaCan International, Announces Appointment of Lynn Schuchter M.D. to its Scientific Advisory Board

24.10.2006

UTEK Corporation and GammaCan International, Inc. Sign a Strategic Alliance

05.10.2006

GammaCan International to Present IgG-Based Melanoma Program at the 14th Annual BioPartnering Europe Conference

20.12.2005

GammaCan Enters Research and Licensing Agreement with Tel Hashomer

15.11.2005

GammaCan Consummates Initial Investment of  USD 500,000 with an Option of up to USD 2.5 Million Financing Through Sal. Oppenheim jr. & Cie. (Switzerland) Ltd

03.11.2005

Gammacan Appoints World Renowned Immunohematologist, Dr. Jacob Nusbacher as Medical Advisor to Oversee Phase II GCAN 101 Clinical Trial Activity and Expand Product Pipeline

21.06.2005

GammaCan Announces 2005 EULAR Prize Awarded to Dr. Yehuda Shoenfeld - Chief Scientific Officer and Inventor of Company’s IVIg Therapy

26.07.2005

GammaCan Reports on Patient Enrollment in Phase II Clinical Trial; Company Pursues Toxicity and Efficacy Study of GCAN 101, Proprietary IVIg Therapy for Metastatic Cancers

28.09.2006

GammaCan International to Present at the 6th Annual Biotech in Europe Investor Forum

18.01.2006

Gammacan Closes Additional USD1.2 Million Investment

21.09.2006

GammaCan International Inc., Appoints Dr. Pearl Grimes, Founder & Director of the Vitiligo and Pigmentation Institute of Southern California, to the Scientific Advisory Board

30.01.2006

Gammacan to Explore the Efficacy of IVIG sourced from Specific Population for the Treatment of Malignant Melanoma Patients

03.02.2006

Gammacan Engages Global Markets Capital Group to Actively Pursue Strategic Alliances in the Blood, Plasma And IVIg Markets

28.02.2006

Gammacan Files Two Provisional Patent Applications for the Treatment of Malignant Melanoma

13.03.2006

GammaCan’s Oncology Program Highlighted at International Plasma Protein Congress

22.03.2006

GammaCan Announces Positive Pre-IND Meeting with the U.S. FDA Regarding VitiGam – the Company’s Novel Treatment for Metastatic Malignant Melanoma

24.04.2006

GammaCan International Appoints Patrick N.J. Schnegelsberg as Chief Executive Officer

10.05.2006

GammaCan International to Webcast Presentation at the 3rd Annual Rodman & Renshaw Global Healthcare Conference

19.06.2006

GammaCan to Present at the MarketReach America Conference in Maryland.

19.09.2006

GammaCan and Tel Ha'Shomer Scientists to Present Phase II Results of the GC 101 Melanoma Trial at the 5th International Congress on Autoimmunity in Sorrento, Italy

14.09.2006

GammaCan and Tel Ha'Shomer Scientists to Present IgG Colon Cancer Abstract at 5th International Congress on Autoimmunity in Sorrento, Italy

21.07.2006

GammaCan International Announces Approval of USD 1M Grant from the BIRD Foundation to Develop Anti-Cancer Therapy Drug; Life Therapeutics to Partner in Joint Study

15.08.2006

GammaCan Participates in 2006 Vitiligo Support National Conference - Company Joins Community in Exploring Treatment Alternatives, Pathology, New Research, Autoimmune Diseases and the Potential of Assisting in the Treatment of Malignant Melanoma.

22.08.2006

GammaCan International and Life Therapeutics Announce the Signing of a Term Sheet for the Development of VitiGam

05.09.2006

GammaCan Announces Appointment of Richard Spritz, M.D. to Scientific Advisory Board; Leading Geneticist and Pediatric Specialist to Assist Company in Researching And Achieving Milestones in its Efforts to Bring VitiGam to The Clinic

26.07.2006

GammaCan Participates in 2006 Vitiligo Support National Conference